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Summary 
Mutations in the protein dysferlin, a member of the ferlin family, lead to limb girdle 
muscular dystrophy type 2B and Myoshi myopathy.  The ferlins are large proteins 
characterised by multiple C2 domains and a single C-terminal membrane spanning 
helix.  However, there is sequence conservation in some of the ferlin family in regions 
outside the C2 domains.  In one annotation of the domain structure of these proteins, 
an unusual internal duplication event has been noted where a putative domain is 
inserted in between the N and C terminal parts of a homologous domain. This domain 
is known as the DysF domain. Here we present the solution structure of the inner 
DysF domain of the dysferlin paralogue myoferlin, which has a unique fold held 
together by stacking of arginine and tryptophans, mutations in which lead to clinical 
disease in dysferlin.
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Introduction 
Limb girdle muscular dystrophy (LGMD) describes a range of progressive muscle 
wasting diseases, which begin with the arms and pelvic girdle and are subclassified 
based on the underlying genetic defect.  Miyoshi myopathy 
1
 is an autosomal 
recessive muscle wasting disease that begins in the distal, posterior leg muscles.  The 
dysferlin gene was identified by reverse genetics as the locus of mutations that lead to 
both autosomal recessive LGMD type 2B 
2
 and Myoshi myopathy 
3
.  Dysferlin was so 
named as it showed homology to the C. elegans gene fer1. Mutations in fer1 cause 
defects in spermatoza motility due to a failure of the immature spermatid to fuse with 
membranous organelles 
4
.    
 
The ferlin family of proteins is characterised by a number of C2 domains, normally 
labelled A, B etc. starting from the N-terminus, and a C-terminal membrane spanning 
helix.  C2 domains were originally characterised as the second homologous region 
amongst isoforms of Ca
2+
-dependent protein kinase C and were subsequently 
identified in a wide range of proteins (for a review see 
5
).  C2 domains consist of 
around 130 residues, which form two four-stranded anti-parallel  sheets, with two 
different topologies known 
6; 7
. C2 domains classically bind phospholipids in a Ca
2+
-
dependent manner, although some domains have been reported to bind to 
phospholipids independent of calcium ions and others have not had any binding 
properties demonstrated for them 
8
.  C2 domains also form protein-protein 
interactions and have been shown to have more than one interaction interface 
9
. 
 
In humans the ferlin family consists of three characterised proteins; dysferlin, 
myoferlin 
10
 and otoferlin 
11
.  Myoferlin has 56% sequence identity to dysferlin and is 
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highly expressed in early differentiating myoblasts, in contrast to dysferlin, which is 
most highly expressed in mature myotubes 
12; 13
. Dysferlin knockout mice show 
defects in Ca
2+
-dependent sarcolemmal membrane repair and accumulate vesicles at 
the sarcolemma 
14
.  Microarray analysis of dysferlin deficient mice identified 
annexins as potential interaction partners and the interaction was confirmed 
experimentally 
15
.  Myoferlin knockout mice show reduced muscle size and smaller 
myofibres, although there is some increase in dysferlin to compensate 
13
.  Conversely 
myoferlin is upregulated in dystrophic and regenerating muscle and myoferlin and 
dysferlin can partially compensate for each other. Otoferlin is mutated in a non-
syndromic form of deafness 
11
. Otoferlin interacts with SNAP25 and SNARE proteins 
and probably acts as the calcium sensor that triggers membrane fusion at auditory cell 
synapses 
16
. 
 
Domain annotation of the various ferlin family members varies significantly between 
the two main sequence based annotation databases Pfam 
17
 and SMART 
18
, although 
they do cross-refer to domains annotated by the other (Figure 1).  The databases do 
not agree on the number of C2 domains.  There are probably seven C2 domains in 
both myoferlin and dysferlin but both the 5
th
 and 7
th
 domains are only weakly 
predicted by both databases with E values > 0.001.   In contrast the C2A domains of 
both dysferlin and myoferlin are classical C2 domains. The C2A domain of dysferlin 
has been shown experimentally to be a Ca
2+
-dependent phospolipid binding domain
12
, 
and the structure of the C2A domain of myoferlin (PDB 2dmh, unpublished) has 
regular type II topology (similar to phospholipase C ).   
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Outside the C2 domains Pfam predicts, for both myoferlin and dysferlin, a FerI 
domain that lies between the C2B and C2C domains, and FerA and FerB, which lie in 
the long stretch between C2C and C2D.  SMART on the other hand does not itself 
contain these three predicted domains, but does propose that dysferlin, myoferlin and 
fer-1 contains two copies of the DysF domain.  The DysF domains in dysferlin, 
myoferlin and fer1 exist as an internal duplication; an inner DysF domain is 
surrounded by the N-terminal and C-terminal (DysFN and DysFC) sections of a 
second outer domain (Fig. 1).  The DysF domain was first reported in Drosophila 
19
. 
Gene CG6468 was examined as it has multiple repeats of a -propeller like domain.  
Much of the remainder of the protein was then found to be homologous to a region of 
dysferlin. However the internal duplication of the DysF domain is only seen in the 
ferlins and not in the -propeller like proteins (which are found in a range of 
eukaryotes).  SMART also finds the DysF domain in some yeast peroxisomal proteins 
that Pfam annotates with the much larger Pex24p domain of unknown function found 
exclusively in fungi.  The DysF domain is not however found in otoferlin, and so its 
role is not general to all ferlin family members. 
 
It is therefore of interest to ascertain whether the DysF domain of the ferlins is a 
structured domain, particularly as a number of disease causing mutations map to this 
region 
20
.  We present here the solution structure of the inner DysF domain of 
myoferlin, the first structure of a DysF domain, which has a novel fold. 
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Results  
Structure of the DysF domain 
The solution structure of human myoferlin residues 923-1040, with an additional 5 
amino acids (IDPFT) arising from the vector on the N-terminus, has been solved.  The 
20 lowest energy conformers compatible with 2810 distance restraints, 87 one bond 
N-H residual dipolar coupling restraints, 48 hydrogen bond restraints and 109 dihedral 
angle restraints (see Table 1) have been deposited in the Protein Data Bank (nxxx) 
and the restraints in the BMRB (BMRB).  The rmsd for these structures is 0.74 Å for 
backbone atoms and 1.14 Å for all atoms (Fig. 2a) 
 
 The structure of the DysF domain consists largely of two long  strands (residues 
929-939 and 1018-1028) orientated antiparallel to each other. The intervening 77 
residues form a long loop, which pack against both sides of the central beta hairpin. 
Several regions of this loop form short stretches of  strand which extend the central 
hairpin to a broken four-stranded sheet (948-954, 974-975, 981-982, 994-996) in an 
anti-parallel manner (Fig.2, Fig 3, Fig 4). The region annotated by SMART as DysFN 
supplies the first strand and around two thirds of the loop (red in Fig.2) and the region 
annotated as DysFC provides a third of the loop and the second strand. The point of 
insertion of the inner DysF domain in the gene duplication is between secondary 
structure elements.  This means that both DysF domains can adopt the same fold, with 
the inner domain emerging from the loop half way along the beta sheet of the outer 
domain.  It is not known whether the two domains are in fixed orientation or flexibly 
connected.  The homologous inner DysF construct from human dysferlin (residues 
935-1067) showed a dispersed HSQC (data not shown) but a full set of 3D 
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experiments was not collectable due to an apparently longer correlation time than 
would be expected for a protein of this size.  This indicates that the myoferlin and 
dysferlin DysF domains are folded.  They would be expected to be similar in structure 
as there is 57% sequence identity 72% sequence similarity between the inner DysF 
domains of dysferlin and myoferlin. 
 
Neither Secondary Structure Matching (SSM) 
21
 nor DALI 
22
 find significant matches 
(highest Z score SSM 4.8 and DALI 4.3). A number of proteins have antiparallel 
strands of roughly the same length and orientation but the connection between the two 
strands in DysF seems to be unique.   
 
The electrostatic surface of the myoferlin inner DysF domain is largely negatively 
charged (Fig 5)  with one positively charged patch corresponding to the region 
between the side chains of K1004 and K1013 (region 1), a small slightly positively 
charged patch due to the side chain of K1029 (region 2) and a neutral strip running up 
one face with a slight positive charge corresponding to the side chain of R1021 
(region 2).  The cavities on the domain are small.  Using SURFNET 
23
 on the core 
domain (residues with over 20 NOES per residue 927-1031) the largest gap region is 
only 612 Å
3
.  Although formally large enough to hold 20-30 atoms, normally cavities 
are much larger than the ligands. Only 12.5% of ligands of 7 atoms or more occupied 
a cleft of less than 1000 Å
3
 
24
, indicating that any molecule that binds to these sites is 
likely to be small maybe only an ion.  There are three electrostatically negative 
cavities of over 550-650 Å
3
 close to S939/T1017 (Region 4), D932/E933/D955 
(Region 5) and D951/D959/K1004/R1020 (Region 6).  The conservation is 
particularly high in regions 5 and 6 (over 75% of residues are present in 60% or more 
page 8 
of DysF domain sequences).  Given the small size and the electrostatics, these could 
be metal ion binding sites although the C2 domains have been presumed to be the 
calcium sensors in membrane repair. The His-Tag cleaved protein is retained on a 
nickel column.  However neither calcium or magnesium ions altered the HSQC, 
although zinc and nickel ions precipitated the sample. 
 
Sequence conservation in DysF domains 
The most highly conserved residues in the DysFN region (conserved in 65% of DysF 
sequences –SMART database) are a YENQ sequence and a number of tryptophans, 
which in myoferlin inner domain are 935YQNE and W946, W973, W975 and W980.  
In the DysFC region the conserved residues are GWxY (992GWEY in myoferlin 
inner domain) at the N-terminal end and RRRxWxR at the C-terminal end (1019 
RRRRLVR in myoferlin inner domain) (see Fig. 3, 4a).  Many of these conserved 
tryptophans and arginines form arginine/aromatic (R/W) stacking interactions, which 
is a well-known structural motif 
25
.   In the DysF domain, the best-defined stack 
consists of W946 and W993 which sandwich R1019. R1021 extends this stack.  
Indeed in other DysF domains this stack may be extended by a further W as the 
equivalent of L1023 in myoferlin is a W in two-thirds of DysF domains. The 
orientations of R1019 and R1021 are buttressed by E938 and Q936 respectively 
(Figure 4b). Further R/W stack motifs are also found for R1025 which is sandwiched 
between W975 and W980, R1020, which is sandwiched between W1008 and Tyr935 
and the W973, R1027 pair. The tryptophans are extremely well defined in the NMR 
structure with an average of over 60 distant restraints per residue (47 is the lowest) 
and the arginines average 50 restraints per residue.  Thus the structural determinants 
of the DysF domain are a combination of positively charged and aromatic residues.   
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A search was performed to look for other examples of R/W stacking using 
JESS 
26
.  Using the four residues W946, R1019, W993 and R1021 as a search motif, 
matches were found in 17 structures in the PDB all of which were growth 
hormone/interleukin receptors.  These receptors have 6 extracellular domains, the 
second and third of which are required for ligand binding. The third domain contains 
a WSXWS motif, which is common to a broad range of growth factor receptors.  In 
some of the receptors, such as gp130 
27
, the residues in this motif form part of a stack 
of three tryptophans and three arginines  that is involved in the structural integrity of 
the domain rather than ligand binding 
28
.  Intriguingly, a recent report implicates 
myoferlin in stabilising the VEGF receptor-2 in endothelial cells 
29
.  A further JESS 
search with residues W970, W980 and R1025 again found the growth factor receptors 
along with thrombospondin repeats (TSR) 
30
, which have 3 tryptophans sandwiching 
two arginines.  TSR are extracellular domains, found in 41 human proteins with up to 
18 repeats in each protein that mediate cell attachment, glycan binding and inhibit 
matrix metalloproteinases. The W/R motif in combination with disulphide bonds are 
thought to give stability to the TSR domain fold.   
 
Disease causing mutations. 
Surveys of patients find mutations throughout the dysferlin gene 
31
 and a single 
hotspot is not apparent.  Of the 91 sites of missense entries in dysferlin in the Leiden 
Muscular Dystrophy Database (LMDD), 12 (13% of the total) map to the inner DysF 
domain, which contains 5.5% of the total protein sequence, so the DysF domain is 
more susceptible to mutation than average for the protein. These include some of the 
most common disease causing mutations R959W (reported 22 times) and W999C 
(reported 15 times).  Disruption of the inner domain of dysferlin, particularly 
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perturbing the W/R stacking is clearly a cause of dysferlinopathy (Table 2; Fig.4c).  
Six of the 12 residues involved in the R/W stacking in the inner DysF domain of 
dysferlin are sites of disease causing mutations (W992R, W999C, R1038Q, R1039W, 
R1044S, R1046H), almost certainly resulting in an unfolded domain in the mutations.  
There is also a mutation in the W/R stacking of the outer domain W930C equivalent 
to W999C in the inner domain 
20
. The polymorphism in the inner DysF region can be 
rationalised. R1022Q (not involved in R/W stacking) is a surface exposed side chain, 
which will tolerate hydrophilic substitution; it is H1003 in the myoferlin inner 
domain.   Clearly disrupting the tight packing of the DysF domain by disrupting the 
W/R stacking causes dysferlinopathy almost certainly due to degradation of unfolded 
protein. 
 
Discussion 
The significant number of disease-causing mutations in the dysferlin gene that map to 
the inner DysF domain demonstrates that this domain must be correctly folded for 
dysferlin to be functional.  However the similarities of the stacked R/W motifs 
between DysF and the growth hormone receptors and thrombospondin domains 
probably represent convergent evolution to a substructure that stabilises small  
sheets rather than indicating a functional similarity.   
How the internal duplication has been tolerated is clear.  The insertion occurs in a 
loop, where extending the loop to include another domain is tolerated.   There are 
mutations reported in the linker region in the Leiden database R1060T and a 
duplication of residues A1064 and E1065, although the latter is reported to be a 
polymorphism in the Italian population but not in East Asian controls 
31
.   This raises 
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the possibility of the relative orientations of the two DysF domains being important as 
the linker is sensitive to mutation.  Domain insertion is not a rare event, especially 
with domains of this length – over 60% of inserted domains are less than 130 
residues, and nearly 80% are less than 175 residues 
32
. It is however rare for this event 
to occur in non-enzymatic proteins and for the parent and insert domains to be the 
same. One example is the PH domain complex of myosin-X, which has a PH domain 
inserted into another PH domain 
33
.  
 
A number of binding partners of dysferlin have been reported (for a recent review see 
34
).  These include annexin A1  
15
, which has been shown to be required for Ca2+-
dependent membrane sealing 
35
, caveolin 3 
36
, which is mutated in limb girdle 
muscular dystrophy type 1C, AHNAK 
37
 and beta-parvin 
38
.  Interaction of dysferlin 
with calpain 3m which is mutated in Limb Girdle Muscular Dystrophy Type 2A, has 
been implied from co-association studies 
39
.  The C-terminus of AHNAK binds to the 
C2A domain of dysferlin and myoferlin 
37
. The first CH domain of  beta-parvin binds 
to the intracellular juxtamembrane section of dysferlin, in fact the pathological 
mutation in the inner DysF domain of dysferlin W999C did not prevent binding to 
beta parvin ruling out disruption of the interaction with beta parvin as a source of the 
pathology 
38
.   
The major candidate for DysF domain binding is caveolin-3, as the scaffold domain of 
caveolin-3 has been shown by phage display enrichment to bind W rich peptides with 
a motif WXWXXXXW 
40
.  There are conserved versions of this motif in the inner 
DysF domains of myoferlin and dysferlin starting at W973 of myoferlin 
36
. In the 
outer domain the spacing is shorter between the second and third W.  Although  W973 
and W975 makes a possible binding surface the third W980 is on the opposite face of 
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the folded DysF domain. This supports the possibility that interaction with caveolin-3 
occurs when the DysF domain is in a denatured state, as an unfolded state much more 
resembles the peptides selected in the Couet study than the mostly buried tryptophans 
in the folded structure, which do not form a single binding surface.  Unfolding of the 
DysF domain could be a mechanism for degrading dysferlin and myoferlin at the end 
of the repair cycle.  Some metals (nickel and zinc) precipitate the domain and this 
could be via aggregation of an unfolded state. 
Our structural studies of the inner DysF domain of myoferlin have allowed us to 
rationalise the molecular basis of a significant number of the missense mutations in 
dysferlin. The structure resolves some of the issues of annotation of domains in the 
ferlins and provides a framework for fully understanding the role of this domain in 
Limb Girdle Muscular Dystrophy. 
 
Materials and Methods 
Sample preparation 
The DysF domain cDNA, encoding residues 923-1040 of Human Myoferlin, was 
cloned into the pET151-D vector (Invitrogen). The recombinant DysF domain was 
over-expressed in Escherichia coli strain BL21 Star (DE3), grown in minimal media 
containing 
15
NH4Cl as the sole nitrogen source, with either 
12
C or 
13
C-glucose as the 
sole carbon source, to produce the uniformly 
15
N- or 
15
N/
13
C-labelled protein. Protein 
expression was induced at an OD600 = 0.5 by the addition of IPTG to a final 
concentration of 0.1 mM for 6 hours. After nickel ion affinity chromatography, the 
sample was treated with TEV protease for 18 hours (4°C) to cleave the His6-tag 
fragment. DysF was then purified by size-exclusion chromatography. 
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NMR Spectroscopy 
Samples for NMR spectroscopy were prepared by exchanging 
15
N or 
15
N/
13
C 
uniformly-labelled DysF protein into buffer containing 20 mM MES, 100 mM NaCl 
and 90% H2O/10% D2O or 100% D2O, pH 6.5, at a final protein concentration of 1.3 
mM.  NMR spectra were acquired at 298 K (except where indicated) on Varian 
UnityPLUS and INOVA spectrometers (operating at nominal 
1
H frequencies of 500 
MHz and 600/800 MHz, respectively) each equipped with a triple resonance (
1
H, 
13
C, 
15
N) probe including a Z-axis pulse field gradient coil. All NMR spectra were 
processed using NMRpipe/NMRDraw 
41
 and analysed using the CCPN Analysis 
package 
42
. 
1
H, 
13
C and 
15
N chemical shifts were referenced indirectly to sodium 2,2-
dimethyl-2-silane-pentane-5-sulphonate (DSS). 
 
Sequence-specific backbone resonance assignments were obtained by combining the 
data from the following 3D gradient sensitivity enhanced triple resonance 
experiments: HNCO, HNCA, HN(CO)CA, HN(CA)CO, HA(CA)NH, 
HA(CACO)NH, HNCACB 
43
 and CBCA(CO)NH 
44
. An assigned 
1
H-
15
N-HSQC is 
shown in Figure 6.  Side-chain resonance assignments were obtained from 3D 
15
N-
separated TOCSY-HSQC (60 ms mixing time) and 3D [
1
H,
13
C]-HCCH-TOCSY (16 
ms) spectra. Distance restraints were derived from 3D 
15
N and 
13
C-edited NOESY-
HSQC (100 ms mixing times). One-bond 
1
H-
15
N residual dipolar couplings were 
obtained from [
1
H,
15
N]-IPAP-HSQC spectra 
45
 acquired at 293 K in the presence and 
absence of 5% n-octyl-penta(ethylene glycol):octanol, 0.96:1 
46
.  
 
Structure Calculations 
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Inter-proton distance restraints were derived from cross-peaks of 3D [
1
H,
15
N]-
NOESY-HSQC and [
1
H,
13
C]-NOESY-HSQC spectra. The cross-peaks of 3D 
[
1
H,
15
N]-NOESY-HSQC were grouped into four categories according to their relative 
peak intensities and were designated with the corresponding interproton distance 
restraint limits of 1.8-2.5 Å, 1.8-3.0 Å, 1.8-3.5 Å and 1.8-4.0 Å. The cross-peaks of 
3D [
1
H,
13
C]-NOESY-HSQC were grouped into five categories according to their 
relative peak intensities and were designated with the corresponding interproton 
distance restraint limits of 1.8-2.5 Å, 1.8-3.0 Å, 1.8-3.5 Å, 1.8-4.0 Å and 1.8-5.0 Å. 
0.5 Å per methyl group was added to the upper bound of the distance restraint for 
NOE cross-peaks that involved methyl groups. 
 
The structure calculations were carried out within the CNS program 
47
 using the 
IUPAC PARALLHDGv5.3 parameter set and TOPALLHDGv5.3 energy function 
parameters for distance geometry calculations and simulated annealing 
48; 49
. The 
ambiguous distance restraints were filtered iteratively, based upon the coordinates of 
an ensemble of intermediate conformers, and duplicate restraints were discarded. A 
total of 2810 NOE-derived inter-proton distance restraints were included in the final 
iterations of the structure calculations. Backbone torsion angle restraints for φ and ψ 
were derived from analysis of 
1
Hα, 
13
Cα, 
13
Cβ, 
13C’ and 15N, HN chemical shift 
databases as implemented in the program TALOS 
50
. 
 
Initial estimates of the value of the axial and rhombic components of the molecular 
alignment tensor were obtained with MODULE 
51
, -20.4 Hz and 0.33 Hz, 
respectively. These values were used as a starting point for a procedure that 
simultaneously refined the protein structure and ascertained the values of the 
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alignment tensor components using a grid search approach. The final values of the 
axial and component and rhombicity of the molecular alignment tensor used in the 
refinement stage were -19.687 Hz and 0.350 Hz, respectively. The final set of 
structures was obtained from water refinement calculations in CNS using modified 
RECOORD protocols 
45
 
52
. The quality of the ensemble of structures was evaluated by 
the PROCHECK program 
53
.  The ensemble of structures and NMR restraints have 
been deposited with the PDB and BMRB (PDB2k20, BMRB 15718) 
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 Figure Legends 
Figure1. Domain Structure and Sequence of the ferlins PFAM and SMART 
domain representations of human myoferlin.   
 
Figure 2. Structure of myoferlin DysF domain a) Ensemble of 20 lowest energy 
structures of myoferlin inner DysF domain with the DysFN domain in red and the 
DysFC domain in green. b) Stereo pair of backbone of lowest energy structure  Figure 
drawn with Pymol 
55
 
 
Figure 3.  Sequence alignment of DysF domains of human dysferlin and myoferlin, 
C.elegans fer-1, yeast peroxisomal protein PEX30 and human -propeller protein 
DKFZP434B0335. The rows correspond to the DysFN and DysFC regions.  
Secondary structure of the myoferlin inner domain is shown.  Figure drawn using 
Espript  
54
. 
 
Figure 4  Conserved and mutated residues a) Conserved residues in ball and stick. 
Arginines in blue, Tryptophans in yellow, tyrosines in red, other residues green. b) 
Close up of residues Q936, E938, W946, Y993, R1019, and R1021.  c) Disease-
causing mutations in ball and stick. Tryptophans and histidines are labelled in yellow, 
arginines in blue, tyrosines in red and alanines in green.  This view is 180 degrees 
away from figure 5a to show the opposite face of the -sheet.  Figure drawn with 
Pymol 
55
 
Figure 5  Electrostatic surface of DysF domain (positive blue, negative red). Left 
and centre views approximately 180 degree rotation apart right view approximately 
90 degrees with respect to central.  Figure drawn with Pymol 
55
. 
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Figure 6.  
1
H-
15
N HSQC of inner DysF domain of human myoferlin  showing 
assignments. Spectrum recorded in 20 mM MES, 100 mM NaCl and 90% H2O/10% 
D2O at 298K. 
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